These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 33475737

  • 1. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial.
    Marsh JC, Stanworth SJ, Pankhurst LA, Kallon D, Gilbertson AZ, Pigden C, Deary AJ, Mora AS, Brown J, Laing ES, Choo LL, Hodge R, Llewelyn CA, Harding K, Sage D, Mijovic A, Mufti GJ, Navarrete CV, Brown CJ.
    Blood; 2021 Jan 21; 137(3):310-322. PubMed ID: 33475737
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases.
    Pai SC, Lo SC, Lin Tsai SJ, Chang JS, Lin DT, Lin KS, Lin LI.
    Transfusion; 2010 Nov 21; 50(11):2318-27. PubMed ID: 20497513
    [Abstract] [Full Text] [Related]

  • 5. Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support?
    Duquesnoy RJ.
    Transfusion; 2008 Feb 21; 48(2):221-7. PubMed ID: 18005328
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR].
    Gao SQ, Xu YP, Luo CR, Li DC, Pen L, Liu T, Zou QC.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb 21; 32(1):242-249. PubMed ID: 38387929
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HLA-matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening.
    Kreuger AL, Mäkelburg ABU, Somers JAE, Tomson B, van de Watering LMG, van der Bom JG, van Kraaij MGJ, Weller CM.
    Transfusion; 2019 Nov 21; 59(11):3303-3307. PubMed ID: 31602653
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C, Doree C, Estcourt LJ, Trivella M, Hopewell S, Brunskill SJ, Stanworth S, Murphy MF.
    Cochrane Database Syst Rev; 2013 Mar 28; (3):CD009072. PubMed ID: 23543569
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients.
    Friedberg RC, Donnelly SF, Mintz PD.
    Transfusion; 1994 Mar 28; 34(3):215-20. PubMed ID: 8146893
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity.
    Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, Gornbein JA, Landaw EM, Smith R, Cecka JM.
    Transfusion; 2000 Dec 28; 40(12):1446-56. PubMed ID: 11134563
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Determination in vivo viability of a transfused platelet product by corrected count increment and percentage platelet response.
    Thuku NW, Shikuku K, Mbugua A.
    Pan Afr Med J; 2017 Dec 28; 27():226. PubMed ID: 28979628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.